Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928364 | 0.78 | NQO2 (0.40) | LMNAPRNPHPGDHTTNPSR1 | |
| SCHEMBL23905532 | 0.78 | KDM4E (0.56) | LMNAPRNPHPGDHTTNPSR1 | |
| SCHEMBL28453161 | 0.78 | HTT (0.40) | LMNAPRNPHPGDHTTNPSR1 | |
| SCHEMBL31328548 | 0.74 | CA12 (0.38) | LMNAPRNPHPGDHTTNPSR1 | |
| SCHEMBL31654043 | 0.74 | PSMD14 (0.45) | LMNAPRNPHPGDHTTNPSR1 | |
| SCHEMBL4202546 | 0.74 | ERN1 (0.37) | — | |
| SCHEMBL18229801 | 0.72 | KDM4E (0.62) | LMNAKDM4E | |
| SCHEMBL21989013 | 0.71 | DYRK1A (0.35) | HPGDHTTNPSR1KDM4E | |
| SCHEMBL23905367 | 0.69 | KDM4E (0.49) | LMNAHPGDHTTNOD2KDM4E | |
| SCHEMBL1571501 | 0.69 | NSD1 (0.41) | LMNAPRNPHPGDHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141911-A1 | Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease | NORTHEASTERN UNIVERSITY | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141911-A1 | Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease | MAPT, PSEN1, PSEN2 | LMNA 1147/4885PRNP 24/4885HPGD 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.